Physician profile
Alisha Kumar
NPI 1225476310
$1,903.97
in general payments reported to CMS, 2019-2025
35 companies · $150 in 2025
The $150 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $338 · 2021: $491 · 2022: $272 · 2023: $172 · 2024: $263 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.36 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $146.41 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $125.70 | 2019-2022 | |
| Abbvie INC. | $125.38 | 2021-2024 | |
| Novo Nordisk INC | $121.84 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $100.38 | 2020-2023 | Mounjaro |
| Amgen INC. | $93.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $90.14 | 2020-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.37 | 2019-2022 | |
| Eisai INC. | $85.54 | 2020-2024 | |
| Glaxosmithkline, LLC. | $64.96 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $63.48 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $62.56 | 2019-2024 | |
| Adlon Therapeutics L.P. | $59.77 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.06 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.58 | 2021-2025 | Caplyta |
| Dexcom, INC. | $47.60 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $34.55 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $32.82 | 2022-2024 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $29.46 | 2022-2023 | |
| Corium, LLC | $24.73 | 2023 | Azstarys |
| Tris Pharma INC | $23.65 | 2022 | |
| Neurocrine Biosciences, INC. | $22.71 | 2025 | |
| Nestle Healthcare Nutrition INC. | $21.25 | 2021 | |
| Collegium Pharmaceutical, INC. | $21.19 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.01 | 2023 | Trulance, Xifaxan |
| Daiichi Sankyo INC. | $20.72 | 2021 | |
| Esperion Therapeutics, INC. | $17.51 | 2020 | |
| Exact Sciences Corporation | $16.11 | 2023 | Cologuard Collection Kit |
| Phadia US INC. | $15.44 | 2023 | Immunocap |
| Allergan, INC. | $15.38 | 2020 | |
| Shire North American Group INC | $15.28 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.01 | 2020 | |
| Acadia Pharmaceuticals INC | $13.25 | 2019 | |
| Azurity Pharmaceuticals, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.